- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC
June 5th 2016, 6:34pm
Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.
Final Phase III Data Uphold CPX-351 Survival Benefit in AML
June 5th 2016, 7:42am
CPX-351 reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary AML.
Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors
June 5th 2016, 6:59am
The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.
Dr. Hainsworth on Selecting Therapy Based on Genetics
June 5th 2016, 2:55am
John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.
Dr. Cavo on Upfront ASCT in Multiple Myeloma
June 5th 2016, 2:48am
Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.
Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes
June 5th 2016, 2:40am
Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.
Nivolumab Safe, Effective in Early Stage Glioblastoma Study
June 5th 2016, 2:07am
Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.
Molecular Targeting Yields Responses in 12 Cancers in Off-Label Indications
June 5th 2016, 12:43am
Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.
Large Study Gives Boost to Liquid Biopsy Testing for Mutations
June 5th 2016, 12:16am
The liquid biopsy testing method correlated closely with mutations described in databases and in some cases from tumor biopsies.
Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment
June 5th 2016, 12:10am
Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.
Combining Atezolizumab With OX40 Agonist Shows Promise in Solid Tumors
June 4th 2016, 10:15pm
A combination regimen of the PD-L1 inhibitor atezolizumab (Tecentriq) and the investigational OX40 agonist MOXR0916 was well tolerated and showed early signs of of antitumor activity in solid tumors.
Carfilzomib/Pomalidomide Regimen Warrants Further Investigation in Refractory Multiple Myeloma
June 4th 2016, 10:03pm
A regimen consisting of carfilzomib, pomalidomide, and dexamethasone merits further investigation for the treatment of patients with multiple myeloma whose disease progresses while on lenalidomide in the earlier stages of disease.
Nivolumab/Ipilimumab Combination Active in Recurrent SCLC
June 4th 2016, 9:01pm
Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.
Study Confirms Adjuvant Intraperitoneal Chemotherapy Is Beneficial and Well Tolerated
June 4th 2016, 4:22am
Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.
Dr. Hochhaus on TFS With Nilotinib in Patients With CML
June 4th 2016, 4:21am
Andreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).
Abemaciclib Active Against HR+/HER2- Breast Cancer
June 4th 2016, 4:18am
The CDK4/6 inhibitor abemaciclib induced a response rate of nearly 20% in heavily pretreated patients with refractory, HR-positive, HER2-negative advanced breast cancer, according to findings from the phase II MONARCH 1 trial.
Isatuximab Monotherapy Effective for Heavily Pretreated Myeloma
June 4th 2016, 3:54am
The anti-CD38 monoclonal antibody isatuximab showed promising signs of activity as a single-agent for patients with heavily pretreated relapsed/refractory multiple myeloma.
Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC
June 4th 2016, 3:38am
Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).
Temozolomide Trial Shows Improved 5-Year Survival Rates in Anaplastic Glioma
June 4th 2016, 3:09am
Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.
Biosimilar Trastuzumab Matches Herceptin in Efficacy and Safety
June 4th 2016, 2:38am
A biosimilar version of trastuzumab demonstrated equivalent efficacy and safety to the FDA-approved branded drug in a randomized phase III study among patients with HER2-positive metastatic breast cancer.